Targeting Anaplastic Lymphoma Kinase (ALK) in Rhabdomyosarcoma (RMS) with the Second-Generation ALK Inhibitor Ceritinib
Anke van Erp(Radboud University Nijmegen), Yvonne M.H. Versleijen‐Jonkers(Radboud University Nijmegen)
Cited by 39
Related Papers
The role of AXL and the <i>in vitro</i> activity of the receptor tyrosine kinase inhibitor BGB324 in Ewing sarcoma
|Oncotarget|2014|47
Olaparib and temozolomide in desmoplastic small round cell tumors: a promising combination in vitro and in vivo
|Journal of Cancer Research and Clinical Oncology|2020|27
Analysis of PD-1, PD-L1, and T-cell infiltration in angiosarcoma pathogenetic subgroups
|Immunologic Research|2022|15